diagnost anim health
pur along reiter buy pt
clinical-stag
develop therapi pet compani
product pipelin includ small molecul
biolog rang indic dog
cat hors
view current cl king meet event calendar coverag univers
calendar
earli indic suggest mirataz see strong traction recent
data suggest compani pipelin big time driver near term
epocat also look like strong candid address larg market
thesi kindr mirataz stand becom new standard cat
inappet lack appetit drive revenu
expect kindr pipelin conserv drug
potenti blockbust repres upsid stock view reiter
buy rate price target
mirataz compani mirataz sale versu
estim consid revenu recogn drug
reorder drug distributor hand sinc mid-
august initi traction far exceed expect compani
report veterinarian clinic around total
estim order mirataz third
alreadi reorder drug
compani made chang compound
time-frame still expect run field effect studi
next coupl month begin pivot zoeti
report dermatolog drug revenu
understand order stronger summer would
impli almost annual run rate drug even
find
kindr attempt
differenti versu zoeti cytopoint though expect zoeti
respons ultim think kindr compound
need truli superior beat zoeti engin like
find novel label expans said
doubt either zoeti kindr troubl market larg
two player though possibl anoth player could join
market howev expect wont occur earliest
requir disclosur end report
number kindr sale versu last year
estim third-quart net oper loss
period last year ep compar
year ago compani oper expens guidanc
remain
aratana acquisit aratana petxa reportedli put
sale coupl week ago think sale would posit
kindr ultim high takeout price would valid busi
model inappet drug address differ speci
right see off-label use speci
think cross-us case complementari rather competit
ultim aratana hand larger compani wouldnt
obviou neg consequ view
hors drug zimeta iv fever hors pre-approv
inspect juli drug approv hand fda
clear manufactur site expect launch
pilot studi alreadi complet zimeta oral
expect drug come market end estim
drug thu model push back
model rais lower revenu estim
respect rais due better traction mirataz
lower revenu due zimeta approv time chang
revenu forecast due
epo-cat zimeta approv time model respect
ep vs
previous ep move
valuat use ev/revenu multipl revenu
estim cash increas
multipl reflect increas confid asset
risk achiev price target
commit fundrais
page
